The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance

Clinical Cancer Research

Volumn 14, Issue 9, 2008, Pages 2519-2526

  Meads, Mark B ^a   Hazlehurst, Lori A ^a   Dalton, William S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AG 957; ANTINEOPLASTIC AGENT; BIBF 1000; BORTEZOMIB; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CILENGITIDE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; FIBRONECTIN; FLICE INHIBITORY PROTEIN; FLUDARABINE; IMATINIB; INTEGRIN; INTERLEUKIN 6; ITF 2357; MELPHALAN; MITOXANTRONE; PACLITAXEL; PLERIXAFOR; PSK 1404; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 4; VINCRISTINE; VITRONECTIN RECEPTOR; CELL ADHESION MOLECULE; CHEMOKINE; IL6 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BONE MARROW; CELL ADHESION; CELL HOMING; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CLINICAL TRIAL; HUMAN; MINIMAL RESIDUAL DISEASE; NEOPLASM; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA CELL; TUMOR CELL; TUMOR ESCAPE; DRUG RESISTANCE; METABOLISM; PATHOLOGY; REVIEW;

BONE MARROW; CELL ADHESION; CELL ADHESION MOLECULES; CELL SURVIVAL; CHEMOKINES; DRUG RESISTANCE, NEOPLASM; HUMANS; INTEGRINS; INTERLEUKIN-6; NEOPLASMS;

EID: 52049103847     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-2223     Document Type: Article

References (81)

1. Coldman AJ, Goldie JH. A stochastic model for the origin and treatment of tumors containing drug- resistant cells. Bull Math Biol 1986;48:279-92.
2. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006:107:1761 -7.
3. Jung Y,Wang J, Schneider A, et al. Regulation of SDF- 1 (CXCL12) production by osteoblasts: a possible mechanism for stem cell homing. Bone 2006;38: 497-508.
4. Sun YX, Schneider A, Jung Y, et al. Skeletal localization and neutralization of the SDF-1 (CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005:20: 318-29.
5. Burger JA, Burkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol 2007;137:288-96.
6. Gazitt Y. Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antilineage-specific antibodies. Leukemia 2004;18:1-10.
7. Burns JM, Summers BC, Wang Y, et al. A novel chemokine receptor for SDF-1 and l-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006:203:2201-13.
8. Alsayed Y, Ngo H, Runnels J, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007;109:2708-17.
9. Juarez J, Dela Pena A, Baraz R, et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia 2007;21:1249-57.
10. Spiegel A, Kollet 0, Peled A, et al. Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling. Blood 2004:103:2900-7.
11. Ratajczak MZ, Zuba-Surma E, Kucia M, Reca R, Wojakowski W, Ratajczak J. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 2006;20:1915-24.
12. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62: 1832-7
13. Yoon Y, Liang Z, Zhang X, et al. CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res 2007;67: 7518-24.
14. Uchida D, Onoue T, Tomizuka Y, et al. Involvement of an autocrine stromal cell derived factor-1/CXCR4 system on the distant metastasis of human oral squamous cell carcinoma. Mol Cancer Res 2007;5:685-94.
15. Burger JA, Tsukada N, Burger M, Zvaifler NJ, DellAquila M, KippsTJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655-63.
16. Zeng Z, Samudio IJ, Munsell M, et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 2006;5:3113-21.
17. Sanz-Rodriguez F, Hidalgo A, Teixido J. Chemokine stromal cell-derived factor-1 α modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001;97:346-51.
18. HartmannTN, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 2005;24:4462-71.
19. Hardin J, MacLeod S, Grigorieva I, et al. Interleukin- 6 prevents dexamethasone-induced myeloma cell death. Blood 1994;84:3063-70.
20. Klein B, Zhang XG, Lu ZY, Bataille R. lnterleukin-6 in human multiple myeloma. Blood 1995:85:863-72.
21. Lichtenstein A,Tu Y, Fady C, Vescio R, Berenson J. lnterleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 1995;162:248-55.
22. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10:105 -15.
23. Cheung WC, Van Ness B. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia 2002;16:1182-8.
24. Frassanito MA, Cusmai A, lodice G, Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001;97:483-9.
25. Voorhees PM, Chen Q, Kuhn DJ, et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 2007;13:6469-78.
26. Lu Y, Zhang J, Dai J, et al. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor Clin Exp Metastasis 2004;21:399-408.
27. Bisping G, Leo R, Wenning D, et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2003;101: 2775-83.
28. Dankbar B, PadroT, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor- stromal cell interactions in multiple myeloma. Blood 2000;95:2630-6.
29. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001;15: 1950-61.
30. Arnulf B, Lecourt S, Soulier J, et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007;21:158-63.
31. Wimberger P, Heubner M, Otterbach F, Fehm T, Kimmig R, Kasimir-Bauer S, Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer. Gynecol Oncol 2007:107:331-8.
32. Duan Z, Foster R, Bell DA, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 2006; 12:5055-63.
33. Hobisch A, Eder IE, PutzT, et al. lnterleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998:58:4640-5.
34. Domingo-Domenech J, Oliva C, Rovira A, et al. Interleukin 6, a nuclear factor-KB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-κB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 2006;12:5578-86.
35. Humphries JD, Byron A, Humphries MJ. Integrin ligands at a glance. J Cell Sci 2006:119:3901 -3.
36. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004;5: 816-26.
37. Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR. Prostatic carcinoma cell migration via α(v)β3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 1999:59:1655-64.
38. Cooper CR, Chay CH, Pienta KJ. The role of α(v)β(3) in prostate cancer progression. Neoplasia 2002;4:191 -4.
39. Weerasinghe D, McHugh KP, Ross FP, Brown EJ, Gisler RH, Imhof BA. A role for the αvβ3 integrin in the transmigration of monocytes. J Cell Biol 1998; 142:595-607.
40. Gruber G, Hess J, Stiefel C, et al. Correlation between the tumoral expression of β3-integrin and outcome in cervical cancer patients who had undergone radiotherapy. Br J Cancer 2005:92:41 -6.
41. Stewart DA, Cooper CR, Sikes RA. Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer. Reprod Biol Endocrinol 2004;2:2.
42. Edlund M, Miyamoto T, Sikes RA, et al. Integrin expression and usage by prostate cancer cell lines on laminin substrata. Cell Growth Differ 2001;12: 99-107
43. Jacobs SC. Spread of prostatic cancer to bone. Urology1983;21:337-44.
44. McCabe NP, De S.Vasanji A, Brainard J, Byzova TV. Prostate cancer specific integrin αvβ3 modulates bone metastatic growth and tissue remodeling. Oncogene 2007;26:6238-43.
45. Oshita F, Kameda Y, Hamanaka N, et al. High expression of integrin β1 and p53 is a greater poor prognostic factor than clinical stage in small-cell lung cancer. Am J Clin Oncol 2004:27:215-9.
46. Yao ES, Zhang H, Chen YY, et al. Increased β1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 2007;67:659-64.
47. White DE, Kurpios NA, Zuo D, et al. Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 2004;6: 159-70.
48. Schadendorf D, Gawlik C, Haney U, Ostmeier H, Suter L, Czarnetzki BM. Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours. J Pathol 1993; 170:429-34.
49. Matsuura N, Puzon-McLaughlin W, Irie A, Morikawa Y, Kakudo K,TakadaY Induction of experimental bone metastasis in mice by transfection of integrin α4β1 into tumor cells. Am J Pathol 1996;148:55-61.
50. Hoyt DG, Rusnak JM, Mannix RJ, Modzelewski RA, Johnson CS, Lazo JS. Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Res 1996;56:4146-9.
51. Hodkinson PS, Elliott T, Wong WS, et al. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through β1 integrin-dependent activation of PI3-kinase. Cell Death Differ 2006;13:1776-88.
52. Aoudjit F, Vuori K. Integrin signaling inhibits pacli-taxel-induced apoptosis in breast cancer cells. Oncogene 2001;20:4995-5004.
53. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93: 1658-67.
54. Damiano JS, Hazlehurst LA, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 2001;15: 1232-9.
55. Hazlehurst LA, Argilagos RF, Emmons M, et al. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Res 2006;66:2338-45.
56. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000;19:4319-27.
57. Hazlehurst LA, Valkov N, Wisner L, et al. Reduction in drug-induced DNA double-strand breaks associated with β1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 2001;98: 1897-903.
58. Yanamandra N, Colaco NM, Parquet NA, et al. Tipi-farnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 2006;12;591-9.
59. Hazlehurst LA, Enkemann SA, Beam CA, et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res 2003; 63:7900-6.
60. Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999;5:662-8.
61. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich Dl. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004:103:3503-10.
62. Jundt F, Probsting KS, Anagnostopoulos I, et al. Jaggedl-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004;103:3511 -5.
63. Lwin T, Hazlehurst LA, Dessureault S, et al. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin li-gase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood 2007;110:1631 -8.
64. 1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. B J Haematol 2006;136:269-75.
65. Shain KH, Landowski TH, Dalton WS. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol 2002;168:2544-53.
66. Aoudjit F, Vuori K. Matrix attachment regulates Fas-induced apoptosis in endothelial cells: a role for c-flip and implications for anoikis. J Cell Biol 2001;152: 633-43.
67. Bellamy WT, Dalton WS, Gleason MC, GroganTM, Trent JM. Development and characterization of a mel-phalan-resistant human multiple myeloma cell line. Cancer Res 1991;51:995-1002.
68. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 2005;106:698-705.
69. Tavor S, Petit I, Porozov S, et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 2004;64;2817 24.
70. Burger M, Hartmann T, Krome M, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 2005;106:1824-30.
71. Bisping G, Kropff M, Wenning D, et al. Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups. Blood 2006:107: 2079-89.
72. Golay J, Cuppini L, Leoni F, et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 2007:21; 1892-900.
73. Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travali S, D'Alessandro N. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 1999;85:134-44.
74. Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol 2007;25:1637-8.
75. Zhao Y, Bachelier R, Treilleux I, et al. Tumor αvβ3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 2007:67:5821-30.
76. Park CC, Zhang H, Pallavicini M, et al. β1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 2006;66:1526-35.
77. Matsunaga T, Takemoto N, Sato T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003;9: 1158-65.
78. Mori Y, Shimizu N, Dallas M, et al. Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 2004;104:2149-54.
79. Cortijo J, Sanz MJ, Iranzo A, et al. A small molecule, orally active, α4β1/α4β7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats. Br J Pharmacol 2006;147:661 -70.
80. Glasner J, Blum H, Wehner V, et al. A small molecule α4β1 antagonist prevents development of murine Lyme arthritis without affecting protective immunity. J Immunol 2005;175:4724-34.
81. Theien BE, Vanderlugt CL, Nickerson-Nutter C, et al. Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE. Blood 2003;102:4464-71.